{"id":213424,"date":"2017-08-25T04:13:57","date_gmt":"2017-08-25T08:13:57","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/canaccord-genuity-keeps-rating-and-raises-price-target-on-stryker-corporation-syk-modern-readers\/"},"modified":"2017-08-25T04:13:57","modified_gmt":"2017-08-25T08:13:57","slug":"canaccord-genuity-keeps-rating-and-raises-price-target-on-stryker-corporation-syk-modern-readers","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/canaccord-genuity-keeps-rating-and-raises-price-target-on-stryker-corporation-syk-modern-readers\/","title":{"rendered":"Canaccord Genuity Keeps Rating And Raises Price Target On Stryker Corporation (SYK) &#8211; Modern Readers"},"content":{"rendered":"<p><p>Advertisement    <\/p>\n<p>    Stryker Corporation (NYSE:SYK).  <\/p>\n<p>    On June 30 analysts at Cantor Fitzgerald starting coverage on    the stock giving it an initial rating of Neutral. On May 16,    2017 Goldman Sachs released its first research report on the    stock by announcing an initial rating of Neutral.  <\/p>\n<p>    In the market the company is trading down by -0.12% since    yesterdays close of $138.36. Additionally the company recently    declared a dividend which will be paid on Tuesday the 31st of    October 2017. The dividend will be $0.425 per share for the    quarter which is $1.70 annualized. The dividend yield will be    $1.17. The ex-dividend date will be on Wednesday the 28th of    June 2017.  <\/p>\n<p>    The stock last traded at $138.19 which is marginally lower than    the 50 day moving average of $144.81 and which is slightly    above the 200 day moving average of $136.90. The 50 day moving    average was down by -4.54% and the 200 day average went up    $1.34 or +0.98%.  <\/p>\n<p>    Stryker Corporation (Stryker), launched on February 20, 1946,    is a medical technology company. The Company offers a range of    medical technologies, including orthopedic, medical and    surgical, and neurotechnology and spine products. The    Businesss segments include Orthopaedics; MedSurg;    Neurotechnology and Spine, and Corporate and Other. The    Orthopaedics segment includes reconstructive (hip and knee) and    trauma implant systems and other related products. The    Businesss MedSurg segment consists of instruments, endoscopy,    medical and sustainability products. The Neurotechnology and    Spine segment includes neurovascular products, spinal implant    systems and other related products..  <\/p>\n<p>    Stryker Corporations P\/E ratio is 30.86 and market    capitalization is 51.71B. As of the last earnings report the    EPS was $4.48 and is projected to be $6.50 for the current year    with 374,063,000 shares outstanding. Analysts expect next    quarters EPS to be $1.95 with next years EPS anticipated to    be $7.11.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Originally posted here: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/www.modernreaders.com\/canaccord-genuity-keeps-rating-and-raises-price-target-on-stryker-corporation-syk\/99856\/larry-kramer\" title=\"Canaccord Genuity Keeps Rating And Raises Price Target On Stryker Corporation (SYK) - Modern Readers\">Canaccord Genuity Keeps Rating And Raises Price Target On Stryker Corporation (SYK) - Modern Readers<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Advertisement Stryker Corporation (NYSE:SYK). On June 30 analysts at Cantor Fitzgerald starting coverage on the stock giving it an initial rating of Neutral. On May 16, 2017 Goldman Sachs released its first research report on the stock by announcing an initial rating of Neutral.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/neurotechnology\/canaccord-genuity-keeps-rating-and-raises-price-target-on-stryker-corporation-syk-modern-readers\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187755],"tags":[],"class_list":["post-213424","post","type-post","status-publish","format-standard","hentry","category-neurotechnology"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/213424"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=213424"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/213424\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=213424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=213424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=213424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}